Trade 95

SELL MRK

0.932990545 shares at $152.24 on 2026-08-19

Reasoning

Execute profit-take per thesis #45 terms: stock at +12.4% (152.37 vs 120.58 cost) decisively exceeds the 10-12% take-profit band. Moderna-Merck cancer vaccine Phase 3 win (signal #11335) validates the core Keytruda-franchise thesis; harvest 45% into strength, retain core for durable catalyst validation. $135 trail governing remainder. High-conviction execution on confirmed catalyst and price level.

Thesis

MRK defensive healthcare — partial profit-take EXECUTED Aug 19 per the thesis's own terms (the Moderna-Merck cancer-vaccine Phase 3 win gapped the stock through the 10-12% take-profit band; ~45% was sold into strength). The retained core is now managed on the post-catalyst trail, not the old cost-based band. The catalyst continues to compound favorably: Aug 20 coverage frames the Phase 3 win as raising the competitive stakes in personalized cancer vaccines with Merck/Moderna in the lead — durable Keytruda-franchise validation, not a one-day squeeze. Healthcare remains the strongest 5d sector (+3.0%) despite a red Aug 20 session (-1.3% 1d). Hold the core as defensive ballast. (long, high confidence)

Outcome

7-day: +2.58% · 30-day: +5.56%

Cited evidence

News

Macro